Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Masatoshi Kudo, Takuji Okusaka et al.|Investigational New Drugs|2018Cited by 49
Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)Tsuyoshi Shirakawa, A. Komori, M. Shimokawa et al.|ESMO Gastrointestinal Oncology|2025Cited by 4